ERYTECH Pharma (Euronext: ERYP; Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drugs in red blood cells (RBCs), today announced the presentation of its novel RBC vesiculation approach at the 24th congress of the European Red Blood Cell Society (ERCS), taking place from April 7 to 11, 2022, in Gazzada Schianno, Italy.
Françoise Horand, Director of R&D Operations, comments: “We are delighted to share the work of our team and our collaborators at the next ERCS congress, and in particular to be able to present the ERYCEVTM technology, based on the innovative use of our patented ERYCAPS® platform to produce extracellular vesicles derived from red blood cells, loaded with active substances. The first results of the characterization of the in vitro biological activity of these previously loaded RBCEVs are very encouraging and make it possible to envisage a future application in immune modulation. »
Gil Beyen, CEO of ERYTECH, adds: “The results that will be presented at the ERCS congress underline the versatility and the great potential of our ERYCAPS® platform. We look forward to discussing development potential with red blood cell scientists and will work to provide updates on ERYCEVTM as the program progresses. »